Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat

•DNA methylation age varies depending on MPN phenotype.•Increased JAK2V617F mutation burden correlates with increased DNA methylation age.•Vorinostat therapy can alter DNA methylation age in PV and ET patients. The myeloproliferative neoplasms (MPNs) are a heterogeneous group of clonal neoplastic disorders. Driver mutations in JAK2, CALR, and MPL genes have been identified in the majority of cases. Alongside these, an increasing number of genes...